Results 51 to 60 of about 20,043 (161)

Integrated HIV and TB Services for the Management of Coinfection in West Africa: A Scoping Review of Strategies, Outcomes, Barriers and Enablers

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aim There is a concern about treatment outcomes for human immunodeficiency virus and tuberculosis infections in West Africa. This has led to a focus on the development of strategies for integrated care; however, data on the barriers and enablers of these strategies are limited.
Chris Mensah Nartey, Adwoa Kumiwa Asare Afrane, Benjamin Tagoe, Awo Afi Kwapong, Seth Kwabena Amponsah   +4 more
wiley   +1 more source

A New Approach to Manufacturing Oral Drug Delivery Systems via Selective Laser Sintering With Water‐Insoluble Biocompatible Thermoplastic Polymers: Gaps, Risks, Challenges, and Future Directions

Macromolecular Materials and Engineering, Volume 311, Issue 8, August 2026.
Selective laser sintering enables the fabrication of personalized oral drug delivery systems using biocompatible thermoplastics such as PA12 and polyethylene, offering controlled release and structural precision. However, high‐energy processing introduces safety concerns, including emissions and micro‐ and nanoplastic formation.
Klara Dorożyńska, Ewelina Baran, Przemysław Dorożyński, Grzegorz Formicki, Piotr Kulinowski   +4 more
wiley   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT TPN171 is a potent phosphodiesterase type 5 inhibitor used to treat pulmonary arterial hypertension and erectile dysfunction, primarily metabolized by CYP3A4. This study aimed to evaluate its drug–drug interaction (DDI) potential and determine the optimal dosing when co‐administered with CYP3A4 modulators.
Guanghui Tian, Tao Chen, Lei Li, Zhiqiang Wang, Hao Yang, Jiaxiang Juan, Yuanqin Duan, Jianghong Pei, Jingying Jia   +8 more
wiley   +1 more source

A Systematic Review of Published Physiologically Based Pharmacokinetic Models for Drug Excretion Into Human Breastmilk: Knowledge Gaps and Opportunities to Optimize Reporting and Modeling Practices

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) modeling is increasingly used to predict infant exposure to medications via breast milk. Existing guidance on reporting of PBPK modeling analyses is unstructured and nonbinding to researchers. We evaluated reporting practices and modeling approaches in published PBPK modeling studies.
Joshua Kiptoo, Davies Otieno, Kenta Yoshida, Neel Deferm, Aida Nakayiwa Kawuma, Francis Williams Ojara, Adeniyi Olagunju, Jackson K. Mukonzo, Catriona Waitt   +8 more
wiley   +1 more source

Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 458-470, August 2026.
RESTORE is a prospective, double‐blind, placebo‐controlled, crossover trial evaluating Lemborexant in cirrhosis at Cipto Mangunkusumo National Referral Hospital. Both 5 and 10 mg doses reduced PSQI by week 2, with sustained benefits post‐crossover. The 5 mg group improved Stroop Test performance, whereas the 10 mg group had prolonged reaction time ...
Rino Alvani Gani, Pitt Akbar, Irsan Hasan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Sarah Melissa Panjaitan, Valerie Josephine Dirjayanto   +7 more
wiley   +1 more source

Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

PLoS ONE, 2015
Efavirenz, a non-nucleoside reverse-transcriptase inhibitor (NNRTI) is one of the most commonly prescribed antiretroviral drugs. The present article provides a systematic overview and meta-analysis of clinical trials comparing efavirenz and other active ...
Joanna Kryst, Paweł Kawalec, Andrzej Pilc   +2 more
doaj   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients

Infection and Drug Resistance, 2023
Tongtong Wang,1,* Yingchu Liu,2,* Chunyu Zhu,1,* Siyuan Yang,3 Di Yang,4 Jiang Xiao,4 Guiju Gao4 1Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2School of General Practice and Continuing Education ...
Wang T, Liu Y, Zhu C, Yang S, Yang D, Xiao J, Gao G   +6 more
doaj  

Shedding Light on Synthetic Autocatalysis: From Conventional Closed‐Shell Chemistries to Overlooked Open‐Shell Occurrences

Chemistry – A European Journal, Volume 32, Issue 28, 25 July 2026.
Why add another catalyst when the product itself holds the power to catalyze its own formation? Autocatalysis in synthetic chemistry enhances reaction efficiency and uncovers novel catalytic behavior across both closed‐shell and open‐shell systems, expanding reactivity and enabling innovative design strategies.
Jaspreet Kaur, Joshua P. Barham
wiley   +1 more source